Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study

Shi, MK; Ma, J; Feng, ML; Liang, L; Chen, HY; Wang, T; Xie, ZH

Wang, T (corresponding author), Nanjing Univ, Nanjing Drum Tower Hosp, Dept Thorac Surg, Affiliated Hosp,Med Sch, Nanjing, Peoples R China.; Xie, ZH (corresponding author), 3D Med Inc, Dept Res & Dev, Shanghai, Peoples R China.

CANCER GENETICS, 2021; 256 (): 62

Abstract

MET exon 14 skipping (METex14) is a validated oncogenic driver in lung cancer and MET tyrosine kinase inhibitors are now available as effective clinic......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索